Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.
CML
HSCT
eradication
graft rejection
reconstitution
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
13
05
2022
received:
09
02
2022
accepted:
17
06
2022
pubmed:
8
7
2022
medline:
19
10
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
Chronic myeloid leukemia (CML) is a rare disease in children and treated with tyrosine kinase inhibitors (TKI) and with allogeneic hematopoietic stem cell transplantation (HSCT) still in many cases. We describe an 8-year-old patient with CML treated with two different TKIs before proceeding to allogeneic HSCT. Despite successful engraftment, prompt rejection of the graft was followed by autologous reconstitution. TKI therapy was reintroduced post-rejection in anticipation of relapse but shortly discontinued due to low white blood cell and neutrophil counts. The patient has remained disease-free over 5 years after graft rejection and without further therapy. This case suggests that even a short antileukemic effect by an allogeneic transplant may succeed in eradicating CML.
Sections du résumé
BACKGROUND
Chronic myeloid leukemia (CML) is a rare disease in children and treated with tyrosine kinase inhibitors (TKI) and with allogeneic hematopoietic stem cell transplantation (HSCT) still in many cases.
CASE
We describe an 8-year-old patient with CML treated with two different TKIs before proceeding to allogeneic HSCT. Despite successful engraftment, prompt rejection of the graft was followed by autologous reconstitution. TKI therapy was reintroduced post-rejection in anticipation of relapse but shortly discontinued due to low white blood cell and neutrophil counts. The patient has remained disease-free over 5 years after graft rejection and without further therapy.
CONCLUSION
This case suggests that even a short antileukemic effect by an allogeneic transplant may succeed in eradicating CML.
Identifiants
pubmed: 35796282
doi: 10.1002/cnr2.1663
pmc: PMC9575499
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1663Informations de copyright
© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Blood. 2006 Jun 1;107(11):4532-9
pubmed: 16469872
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):106-112
pubmed: 34889388
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167
pubmed: 30504305
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Leukemia. 2021 Aug;35(8):2199-2204
pubmed: 34002028
Bone Marrow Transplant. 2000 Dec;26(11):1173-7
pubmed: 11149727
Blood. 2015 May 21;125(21):3230-5
pubmed: 25852053
Br J Haematol. 2015 Jan;168(2):305-8
pubmed: 25160793
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Bone Marrow Transplant. 2001 Oct;28(7):717-20
pubmed: 11704798
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Lancet Haematol. 2021 Feb;8(2):e101-e104
pubmed: 33513367
Blood. 2016 Jan 28;127(4):392-9
pubmed: 26511135
Blood. 2019 May 30;133(22):2374-2384
pubmed: 30917954
Br J Haematol. 2020 Mar;188(6):e101-e105
pubmed: 32087030
Lancet. 2008 Jul 12;372(9633):111-112
pubmed: 18620939
Bone Marrow Transplant. 1998 Sep;22(6):599-601
pubmed: 9758352
Pediatr Blood Cancer. 2014 Feb;61(2):355-7
pubmed: 24106110
Cancer Rep (Hoboken). 2022 Oct;5(10):e1663
pubmed: 35796282
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Blood. 2011 Jan 20;117(3):755-63
pubmed: 20966165
Br J Haematol. 2014 Oct;167(1):33-47
pubmed: 24976289
Br J Haematol. 1994 Aug;87(4):867-70
pubmed: 7986732
Haematologica. 2013 Mar;98(3):e25-7
pubmed: 22983586
Pediatr Blood Cancer. 2020 Sep;67(9):e28491
pubmed: 32589368
Bone Marrow Transplant. 1998 Jan;21(1):101-3
pubmed: 9486504